Lepu Biopharma Co., Ltd.
HKSE: 2157.HK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Hong Kong Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Zhongjie Pu
- Employees
- 498
- Headquarters
- Shanghai, China
- IPO year
- 2022
- Market cap
- HK$9.5B
- Website
- https://www.lepubiopharma.com
Loading 2157…
Loading profile data…Frequently asked questions about 2157
What does Lepu Biopharma Co., Ltd. (2157.HK) do?
Lepu Biopharma Co., Ltd., a biopharmaceutical company, focuses on developing oncology therapeutics with a pipeline designed with a range of oncology products in China. The company develops oncology drug candidates, including antibody-drug conjugates (ADC), oncolytic virus drugs, and immunotherapies. It develops immuno-oncology products, such as...
Where does 2157.HK trade?
Lepu Biopharma Co., Ltd. (2157.HK) trades on the Hong Kong Stock Exchange.
What sector is 2157.HK in?
Lepu Biopharma Co., Ltd. (2157.HK) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Lepu Biopharma Co., Ltd.?
Zhongjie Pu is the chief executive officer of Lepu Biopharma Co., Ltd. (2157.HK).
Where is Lepu Biopharma Co., Ltd. headquartered?
Lepu Biopharma Co., Ltd. is headquartered in China.
Does 2157.HK pay a dividend?
Lepu Biopharma Co., Ltd. (2157.HK) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 2157.HK go public?
Lepu Biopharma Co., Ltd. (2157.HK) completed its initial public offering in 2022.